United States Biotechnology & Medical Research

Adicet Bio Inc (ACET)

Track

Track

Adicet Bio Inc experienced notable insider trading activity, with the most recent transactions occurring in April 2026. During this period, OrbiMed entities executed multiple sales and proposed divestments of company shares. These actions follow earlier buying patterns observed in February 2026 by RA Capital Management, reflecting varied capital movements by major shareholders over recent months.
Ticker: ACET Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Adicet Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
179.07
Quantity 69,918 -16.9%
Value US$4,118,316
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
26.59
Quantity 7,692 -7.1%
Value US$4,759,170
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
6.38
Quantity 2,400 -6.9%
Value US$15,312
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
6.53
Quantity 29,319 -45.6%
Value US$191,453
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
1.00
Quantity 3,500,000 +353.4%
Value US$3,500,000
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
1.00
Quantity 1,500,000 +19.9%
Value US$1,500,000
3.9
Kauffman Michael Non-Executive Director
Transaction date
Sale
Price
1.43
Quantity 5,900 -50.0%
Value US$8,437
3.9
Kauffman Michael Director Non-Executive Director
Transaction date
Proposed sale
Price
1.43
Quantity 5,900
Value US$8,437
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.40
Quantity 1,041,700 +486.1%
Value US$2,500,080
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.40
Quantity 242,200 +32.4%
Value US$581,280
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.40
Quantity 1,841,100 +32.4%
Value US$4,418,640
1.6
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.40
Quantity 1,041,700 +486.1%
Value US$2,500,080
1.6
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.40
Quantity 242,200 +32.4%
Value US$581,280
1.6
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.40
Quantity 1,841,100 +32.4%
Value US$4,418,640
1.6
Schor Chen President & CEO Executive Director
Transaction date
Purchase
Price
1.33
Quantity 5,500 +14.5%
Value US$7,340
1.6
Schor Chen President & CEO Executive Director
Transaction date
Sale
Price
1.36
Quantity 5,500 -3.0%
Value US$7,481
1.6
CHEN SCHOR Officer; Director Executive Director
Transaction date
Proposed sale
Price
1.36
Quantity 5,500
Value US$7,481
1.6
Schor Chen President & CEO Executive Director
Transaction date
Purchase
Price
1.42
Quantity 5,500 +3.1%
Value US$7,810
1.6
Schor Chen President & CEO Executive Director
Transaction date
Sale
Price
1.42
Quantity 5,500 -12.7%
Value US$7,810
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 58,000 +8.4%
Value US$121,220
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 442,000 +8.4%
Value US$923,780
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 250,000 +63.0%
Value US$522,500
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 125,000 +13.8%
Value US$261,250
1.6
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 58,000 +8.4%
Value US$121,220
1.6
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 442,000 +8.4%
Value US$923,780
1.6
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 250,000 +63.0%
Value US$522,500
1.6
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.09
Quantity 125,000 +13.8%
Value US$261,250
Healey Don Chief Technology Officer Officer
Transaction date
Planned sale
Price
7.57
Quantity 4,533 -6.4%
Value US$34,327
Healey Don Chief Technology Officer Officer
Transaction date
Planned sale
Price
7.98
Quantity 10,467 -12.8%
Value US$83,476
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
20.06
Quantity 30,000 -36.0%
Value US$601,920
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
21.03
Quantity 9,955 -9.8%
Value US$209,322
Aftab Blake Chief Scientific Officer Officer
Transaction date
Planned sale
Price
21.00
Quantity 6,967 -19.8%
Value US$146,307
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
19.05
Quantity 30,000 -26.4%
Value US$571,488
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
18.04
Quantity 24,813 -17.9%
Value US$447,718
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
18.00
Quantity 500 -0.4%
Value US$9,000
Aftab Blake Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.27
Quantity 8,067 -18.7%
Value US$131,250
Aftab Blake Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.40
Quantity 1,646 -3.1%
Value US$25,348
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
18.00
Quantity 952 -0.7%
Value US$17,136
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
18.01
Quantity 3,371 -2.4%
Value US$60,713
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
18.00
Quantity 200 -0.1%
Value US$3,600
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
16.77
Quantity 66,747 -100.0%
Value US$1,119,307
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
16.51
Quantity 8,094 -10.8%
Value US$133,601
Aftab Blake Chief Scientific Officer Officer
Transaction date
Planned sale
Price
18.00
Quantity 6,968 -15.2%
Value US$125,424
Aftab Blake Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.64
Quantity 6,968 -13.2%
Value US$115,948
Aftab Blake Chief Scientific Officer Officer
Transaction date
Planned sale
Price
14.50
Quantity 1,363 -2.5%
Value US$19,764
Galimi Francesco SVP & Chief Medical Officer Officer
Transaction date
Planned sale
Price
21.00
Quantity 1,775 -2.9%
Value US$37,275
Galimi Francesco SVP & Chief Medical Officer Officer
Transaction date
Planned sale
Price
21.00
Quantity 168 -0.3%
Value US$3,528
Galimi Francesco SVP & Chief Medical Officer Officer
Transaction date
Planned sale
Price
21.00
Quantity 6,036 -9.2%
Value US$126,756
Galimi Francesco SVP & Chief Medical Officer Officer
Transaction date
Planned sale
Price
21.00
Quantity 7,621 -11.3%
Value US$160,041
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.00
Quantity 2,000 -0.6%
Value US$28,000
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.00
Quantity 2,000 -0.6%
Value US$28,000
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.83
Quantity 2,000 -0.6%
Value US$29,664
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.83
Quantity 2,000 -0.6%
Value US$29,664
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.03
Quantity 4,000 -1.1%
Value US$56,121
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.03
Quantity 4,000 -1.1%
Value US$56,118
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
16.90
Quantity 2,000 -0.5%
Value US$33,799
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
16.93
Quantity 2,000 -0.5%
Value US$33,864
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
18.02
Quantity 6,000 -1.6%
Value US$108,131
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
18.02
Quantity 6,000 -1.6%
Value US$108,125
3.4
Sinclair Andrew Non-Executive Director
Transaction date
Purchase
Price
14.00
Quantity 500,000 +30.5%
Value US$7,000,000
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
11.16
Quantity 1,923 -0.9%
Value US$21,454
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
11.16
Quantity 1,924 -0.9%
Value US$21,465
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
12.06
Quantity 8,982 -8.3%
Value US$108,279
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
12.06
Quantity 7,484 -8.3%
Value US$90,220
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.23
Quantity 900 -0.4%
Value US$12,805
Jakobovits Aya Non-Executive Director
Transaction date
Planned sale
Price
14.23
Quantity 892 -0.4%
Value US$12,692
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
13.73
Quantity 733 -0.7%
Value US$10,062
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
13.42
Quantity 8,249 -7.1%
Value US$110,728
1.6
Schor Chen President & CEO Executive Director
Transaction date
Planned sale
Price
13.73
Quantity 612 -0.7%
Value US$8,401
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-09 2026-04-09 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
47,831
434.53
US$1,547,565 		47,831 434.53 US$1,547,565
2026-04-09 2026-04-08 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
69,918 -16.9%
179.07
US$4,118,316 		69,918 -16.9% 179.07 US$4,118,316
2026-04-09 2026-04-08 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
7,692 -7.1%
26.59
US$4,759,170 		7,692 -7.1% 26.59 US$4,759,170
2026-04-08 2026-04-08 PrS Proposed sale
OrbiMed Israel Partners II, L.P.

Shareholder
40,416
6.55
US$264,725 		40,416 6.55 US$264,725
2026-04-09 2026-04-07 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
2,400 -6.9%
6.38
US$15,312 		2,400 -6.9% 6.38 US$15,312
2026-04-09 2026-04-07 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
29,319 -45.6%
6.53
US$191,453 		29,319 -45.6% 6.53 US$191,453
2026-04-07 2026-04-07 PrS Proposed sale
3.9
OrbiMed Israel Partners Limited Partnership

Shareholder
64,242
6.43
US$413,076 		64,242 6.43 US$413,076
2026-04-13 2026-02-20 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,751 +6.7%
7.27
US$543,440 		74,751 +6.7% 7.27 US$543,440
2026-04-13 2026-02-19 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,268 +7.2%
7.21
US$535,472 		74,268 +7.2% 7.21 US$535,472
2026-04-13 2026-02-18 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
74,577 +7.8%
7.04
US$525,022 		74,577 +7.8% 7.04 US$525,022
2025-10-10 2025-10-08 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
3,500,000 +353.4%
1.00
US$3,500,000 		3,500,000 +353.4% 1.00 US$3,500,000
2025-10-10 2025-10-08 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,500,000 +19.9%
1.00
US$1,500,000 		1,500,000 +19.9% 1.00 US$1,500,000
2024-06-07 2024-06-05 S Sale
3.9
Kauffman Michael
Non-Executive Director
5,900 -50.0%
1.43
US$8,437 		5,900 -50.0% 1.43 US$8,437
2024-06-05 2024-06-05 PrS Proposed sale
3.9
Kauffman Michael

Director

Non-Executive Director
5,900
1.43
US$8,437 		5,900 1.43 US$8,437
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,041,700 +486.1%
2.40
US$2,500,080 		1,041,700 +486.1% 2.40 US$2,500,080
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
242,200 +32.4%
2.40
US$581,280 		242,200 +32.4% 2.40 US$581,280
2024-01-26 2024-01-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,841,100 +32.4%
2.40
US$4,418,640 		1,841,100 +32.4% 2.40 US$4,418,640
2024-01-26 2024-01-25 B Purchase
1.6
GORDON CARL L
Non-Executive Director Large shareholder
1,041,700 +486.1%
2.40
US$2,500,080 		1,041,700 +486.1% 2.40 US$2,500,080
2024-01-26 2024-01-25 B Purchase
1.6
GORDON CARL L
Non-Executive Director Large shareholder
242,200 +32.4%
2.40
US$581,280 		242,200 +32.4% 2.40 US$581,280
2024-01-26 2024-01-25 B Purchase
1.6
GORDON CARL L
Non-Executive Director Large shareholder
1,841,100 +32.4%
2.40
US$4,418,640 		1,841,100 +32.4% 2.40 US$4,418,640
2023-10-02 2023-10-02 B Purchase
1.6
Schor Chen

President & CEO

Executive Director
5,500 +14.5%
1.33
US$7,340 		5,500 +14.5% 1.33 US$7,340
2023-10-02 2023-09-29 S Sale
1.6
Schor Chen

President & CEO

Executive Director
5,500 -3.0%
1.36
US$7,481 		5,500 -3.0% 1.36 US$7,481
2023-09-29 2023-09-29 PrS Proposed sale
1.6
CHEN SCHOR

Officer; Director

Executive Director
5,500
1.36
US$7,481 		5,500 1.36 US$7,481
2023-10-02 2023-09-28 B Purchase
1.6
Schor Chen

President & CEO

Executive Director
5,500 +3.1%
1.42
US$7,810 		5,500 +3.1% 1.42 US$7,810
2023-10-02 2023-09-28 S Sale
1.6
Schor Chen

President & CEO

Executive Director
5,500 -12.7%
1.42
US$7,810 		5,500 -12.7% 1.42 US$7,810
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
58,000 +8.4%
2.09
US$121,220 		58,000 +8.4% 2.09 US$121,220
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
442,000 +8.4%
2.09
US$923,780 		442,000 +8.4% 2.09 US$923,780
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
250,000 +63.0%
2.09
US$522,500 		250,000 +63.0% 2.09 US$522,500
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
125,000 +13.8%
2.09
US$261,250 		125,000 +13.8% 2.09 US$261,250
2023-06-29 2023-06-27 B Purchase
1.6
GORDON CARL L
Non-Executive Director Large shareholder
58,000 +8.4%
2.09
US$121,220 		58,000 +8.4% 2.09 US$121,220
2023-06-29 2023-06-27 B Purchase
1.6
GORDON CARL L
Non-Executive Director Large shareholder
442,000 +8.4%
2.09
US$923,780 		442,000 +8.4% 2.09 US$923,780
2023-06-29 2023-06-27 B Purchase
1.6
GORDON CARL L
Non-Executive Director Large shareholder
250,000 +63.0%
2.09
US$522,500 		250,000 +63.0% 2.09 US$522,500
2023-06-29 2023-06-27 B Purchase
1.6
GORDON CARL L
Non-Executive Director Large shareholder
125,000 +13.8%
2.09
US$261,250 		125,000 +13.8% 2.09 US$261,250
2023-02-17 2023-02-15 PlS Planned sale
Healey Don

Chief Technology Officer

Officer
4,533 -6.4%
7.57
US$34,327 		4,533 -6.4% 7.57 US$34,327
2023-02-14 2023-02-10 PlS Planned sale
Healey Don

Chief Technology Officer

Officer
10,467 -12.8%
7.98
US$83,476 		10,467 -12.8% 7.98 US$83,476
2022-11-15 2022-11-10 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
30,000 -36.0%
20.06
US$601,920 		30,000 -36.0% 20.06 US$601,920
2022-11-15 2022-11-10 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
9,955 -9.8%
21.03
US$209,322 		9,955 -9.8% 21.03 US$209,322
2022-11-15 2022-11-10 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
6,967 -19.8%
21.00
US$146,307 		6,967 -19.8% 21.00 US$146,307
2022-11-09 2022-11-07 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
30,000 -26.4%
19.05
US$571,488 		30,000 -26.4% 19.05 US$571,488
2022-11-04 2022-11-03 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
24,813 -17.9%
18.04
US$447,718 		24,813 -17.9% 18.04 US$447,718
2022-11-04 2022-11-02 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
500 -0.4%
18.00
US$9,000 		500 -0.4% 18.00 US$9,000
2022-10-21 2022-10-19 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
8,067 -18.7%
16.27
US$131,250 		8,067 -18.7% 16.27 US$131,250
2022-10-14 2022-10-12 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
1,646 -3.1%
15.40
US$25,348 		1,646 -3.1% 15.40 US$25,348
2022-09-16 2022-09-14 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
952 -0.7%
18.00
US$17,136 		952 -0.7% 18.00 US$17,136
2022-09-13 2022-09-13 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
3,371 -2.4%
18.01
US$60,713 		3,371 -2.4% 18.01 US$60,713
2022-09-13 2022-09-12 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
200 -0.1%
18.00
US$3,600 		200 -0.1% 18.00 US$3,600
2022-09-13 2022-09-12 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
66,747 -100.0%
16.77
US$1,119,307 		66,747 -100.0% 16.77 US$1,119,307
2022-09-13 2022-09-09 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
8,094 -10.8%
16.51
US$133,601 		8,094 -10.8% 16.51 US$133,601
2022-08-05 2022-08-03 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
6,968 -15.2%
18.00
US$125,424 		6,968 -15.2% 18.00 US$125,424
2022-08-03 2022-08-01 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
6,968 -13.2%
16.64
US$115,948 		6,968 -13.2% 16.64 US$115,948
2022-07-07 2022-07-05 PlS Planned sale
Aftab Blake

Chief Scientific Officer

Officer
1,363 -2.5%
14.50
US$19,764 		1,363 -2.5% 14.50 US$19,764
2022-04-05 2022-04-04 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
1,775 -2.9%
21.00
US$37,275 		1,775 -2.9% 21.00 US$37,275
2022-04-05 2022-04-04 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
168 -0.3%
21.00
US$3,528 		168 -0.3% 21.00 US$3,528
2022-04-05 2022-04-04 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
6,036 -9.2%
21.00
US$126,756 		6,036 -9.2% 21.00 US$126,756
2022-04-05 2022-04-01 PlS Planned sale
Galimi Francesco

SVP & Chief Medical Officer

Officer
7,621 -11.3%
21.00
US$160,041 		7,621 -11.3% 21.00 US$160,041
2022-03-11 2022-03-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.00
US$28,000 		2,000 -0.6% 14.00 US$28,000
2022-03-11 2022-03-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.00
US$28,000 		2,000 -0.6% 14.00 US$28,000
2022-02-17 2022-02-16 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.83
US$29,664 		2,000 -0.6% 14.83 US$29,664
2022-02-17 2022-02-16 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.6%
14.83
US$29,664 		2,000 -0.6% 14.83 US$29,664
2022-02-14 2022-02-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
4,000 -1.1%
14.03
US$56,121 		4,000 -1.1% 14.03 US$56,121
2022-02-14 2022-02-09 PlS Planned sale
Jakobovits Aya
Non-Executive Director
4,000 -1.1%
14.03
US$56,118 		4,000 -1.1% 14.03 US$56,118
2022-02-14 2022-01-05 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.5%
16.90
US$33,799 		2,000 -0.5% 16.90 US$33,799
2022-02-14 2022-01-05 PlS Planned sale
Jakobovits Aya
Non-Executive Director
2,000 -0.5%
16.93
US$33,864 		2,000 -0.5% 16.93 US$33,864
2022-02-14 2022-01-03 PlS Planned sale
Jakobovits Aya
Non-Executive Director
6,000 -1.6%
18.02
US$108,131 		6,000 -1.6% 18.02 US$108,131
2022-02-14 2022-01-03 PlS Planned sale
Jakobovits Aya
Non-Executive Director
6,000 -1.6%
18.02
US$108,125 		6,000 -1.6% 18.02 US$108,125
2021-12-10 2021-12-08 B Purchase
3.4
Sinclair Andrew
Non-Executive Director
500,000 +30.5%
14.00
US$7,000,000 		500,000 +30.5% 14.00 US$7,000,000
2021-06-17 2021-06-15 PlS Planned sale
Jakobovits Aya
Non-Executive Director
1,923 -0.9%
11.16
US$21,454 		1,923 -0.9% 11.16 US$21,454
2021-06-17 2021-06-15 PlS Planned sale
Jakobovits Aya
Non-Executive Director
1,924 -0.9%
11.16
US$21,465 		1,924 -0.9% 11.16 US$21,465
2021-06-07 2021-06-03 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
8,982 -8.3%
12.06
US$108,279 		8,982 -8.3% 12.06 US$108,279
2021-06-07 2021-06-03 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
7,484 -8.3%
12.06
US$90,220 		7,484 -8.3% 12.06 US$90,220
2021-05-20 2021-05-20 PlS Planned sale
Jakobovits Aya
Non-Executive Director
900 -0.4%
14.23
US$12,805 		900 -0.4% 14.23 US$12,805
2021-05-20 2021-05-20 PlS Planned sale
Jakobovits Aya
Non-Executive Director
892 -0.4%
14.23
US$12,692 		892 -0.4% 14.23 US$12,692
2021-05-21 2021-05-19 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
733 -0.7%
13.73
US$10,062 		733 -0.7% 13.73 US$10,062
2021-05-21 2021-05-19 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
8,249 -7.1%
13.42
US$110,728 		8,249 -7.1% 13.42 US$110,728
2021-05-21 2021-05-19 PlS Planned sale
1.6
Schor Chen

President & CEO

Executive Director
612 -0.7%
13.73
US$8,401 		612 -0.7% 13.73 US$8,401
Explore more

More insider trading research around Adicet Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America